An interventional study of Intracranial Stent (Tonbridge) in Intracranial Atherosclerosis, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Not yet recruiting at 14 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-25.
Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.
Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 with no phase, reaches primary completion later than 0 of the 27 other live ones, and was the 20th registered.
103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.
Browse Intracranial Arteriosclerosis studies →28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Peking Union Medical College Hospital · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+ · Healthy volunteers
Qianfoshan Hospital · Sites in China
Ages 18–80
Fujian Medical University Union Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3 · Phase 4 8
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is below the median of 195 across 62 interventional studies indexed under Intracranial Arteriosclerosis.
Median enrollment 200 across the 27 interventional studies, 300 across the 17 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 44 have an industry lead sponsor. The 10 most frequent:
Zhuhai Tonbridge Medical Tech. Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Zhuhai Tonbridge Medical Tech. Co., Ltd. has 1 study filed under Intracranial Arteriosclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Intracranial Arteriosclerosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925971Phase 3MicroPort NeuroTech Co., Ltd.A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease(TARGET-DREAM) | 2027-10-01 |
| NCT07445581Jinggang Xia, MDTanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients | 2026-12-31 |
| NCT06881420Fujian Medical University Union HospitalBASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease | 2026-12-31 |
| NCT05550077jiaoliqunOptical Coherence Tomography for Intracranial Atherosclerotic Stenosis | 2026-12-31 |
| NCT07927569Qianfoshan HospitalIntegrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA Occlusion | 2027-01-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 44 studies in Intracranial Arteriosclerosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of intracranial atherosclerotic stenosis.
This is a prospective, multicenter, single-arm clinical trial carried out in 14 centers throughout China. 156 subjects with intracranial atherosclerotic stenosis will be treated with the Intracranial Stent (Tonbridge) for the expansion of vascular stenosis site. The primary objective of this study is to evaluate the effectiveness and safety of the intracranial stent for endovascular treatment of intracranial atherosclerotic stenosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd. ).
Device: Intracranial Stent (Tonbridge)
The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
Incidence of in-stent restenosis at 6 months
The in-stent restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss. The degree of intracranial artery stenosis are measured qualitatively in DSA examination. WASID study will be used to measure the degree of intracranial artery stenosis.
Time frame: 6 months post-procedure
Device success rate and procedural success rate
Device success refers to the successful delivery of the stent to the lesion site through the delivery system during procedure, and it is released smoothly and fits well with the vessel wall without bending and displacement; procedural success is defined as stenosis degree less than 30% immediately after procedure.
Time frame: Intraoperation
Incidence of symptomatic in-stent restenosis at 6 months, 1 year, and 2 years
Symptomatic in-stent restenosis is defined as ischemic stroke or TIA or other ischemic neurological symptoms which are caused by in-stent restenosis.
Time frame: 6 months, 1 year, and 2 years post-procedure
Ratio of mRS 0-2 at 30 days, 6 months, 1 year, and 2 years
Subjects will be evaluated at the follow-up visits according to the mRS. The mRS 0-2 indicates a good prognosis.
Time frame: 30 days, 6 months, 1 year, and 2 years post-procedure
Incidence of stent restenosis at 1 and 2 years
Restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss.
Time frame: 1 and 2 years post-procedure
Incidence of any stroke and death within 30 days
Stroke includes both ischemic and hemorrhagic strokes. Deaths from any cause are included in this data.
Time frame: Within 30 days post-procedure
Mortality at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
Incidence of ischemic stroke in the target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
Incidence of ischemic stroke in non-target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
The incidence of any hemorrhagic stroke at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
Incidence of device deficiency
Device deficiency is the unreasonable risk that may endanger human health or life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc. Possible device deficiency: labeling errors, product quality problems, design defects, broken sterilization packaging, etc.
Time frame: After use of device to end of study
Incidence of adverse events (AE) at 30 days, 6 months, 1 year, and 2 years
Time frame: Through 2 years post-procedure
Incidence of serious adverse events (SAE) at 30 days, 6 months, 1 year, and 2 years
Time frame: Through 2 years post-procedure
Start is estimated for Nov 2022; primary completion for Nov 2023, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriosclerosis →
Zhuhai Tonbridge Medical Tech. Co., Ltd.